To conclude, oral administration of mEVs attenuated intestinal inflammation via inhibiting TLR4-NF-κB and NLRP3 signaling pathways, restoring Treg/Th17 cell balance and the gut microbiota, thus prevented disease progression of colitis. This evidence concerns the gene NFKB1 and colitis.